X-ZELL taking centre stage at inaugural A*CCELERATE NOW expo Singapore, November 2018 – X-ZELL has been one of eight promising biotechnology start-ups selected to exhibit at the inaugural A*CCELERATE NOW exhibition in Singapore. The landmark event – held in a move to...
X-ZELL to present at EMUC18 Amsterdam, November 2018 – X-ZELL CEO, Dr Sebastian Bhakdi, has been invited to join the 2018 European Multidisciplinary Congress on Urological Cancers (#EMUC18) in Amsterdam next month as a plenary speaker. Dr Bhakdi’s addition to the...
X-ZELL officially incorporated in Singapore Singapore, October 2018 – X-ZELL, only recently named one of Asia’s 20 most innovative health tech start-ups, is coming to Singapore. According to X-ZELL CEO, Dr Sebastian Bhakdi, the rare cell detection specialist’s global...
X-ZELL among Asia's 20 most innovative health-tech start-ups Singapore, September 2018 – Galen Growth, a Singapore-based analytics and advisory firm specialising in cutting-edge healthcare technology, has named X-ZELL as one of the 20 most innovative health technology...
Ground-breaking X-ZELL research featured in BJU International Oxford, August 2018 – X-ZELL CEO, Dr Sebastian Bhakdi, has published new research into the utility of tumour-associated Circulating Endothelial Cells (tCEC) for the detection of early-stage prostate cancer....
Applications for global Cryoimmunostaining™ technology trial now open Bangkok, July 2018 – After successfully completing a series of clinical trials across Southeast Asia, atypical cell detection specialist X-ZELL is now making the company’s patented...
